COST-EFFECTIVENESS OF VARENICLINE VERSUS EXISTING SMOKING CESSATION STRATEGIES IN BRAZIL FROM THE PUBLIC PERSPECTIVE, USING THE BENESCO MODEL

被引：0
|
作者：
Fujii, R. [1 ]
Correia, E. A. [1 ]
Mould, J. F. [2 ]
机构：
[1] Pfizer Pharmaceut Inc, Sao Paulo, Brazil
[2] Pfizer Inc, New York, NY USA
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 07期
关键词：
D O I：
10.1016/j.jval.2011.08.1388
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A487 / A487
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness of varenicline and three different behavioral treatment formats for smoking cessation
    Javitz, Harold S.
    Zbikowski, Susan M.
    Deprey, Mona
    McAfee, Timothy A.
    McClure, Jennifer B.
    Richards, Julie
    Catz, Sheryl L.
    Jack, Lisa M.
    Swan, Gary E.
    TRANSLATIONAL BEHAVIORAL MEDICINE, 2011, 1 (01) : 182 - 190
  • [22] Cost Effectiveness of Varenicline in Belgium, Compared with Bupropion, Nicotine Replacement Therapy, Brief Counselling and Unaided Smoking CessationA BENESCO Markov Cost-Effectiveness Analysis
    Lieven Annemans
    Kristiaan Nackaerts
    Pierre Bartsch
    Jacques Prignot
    Sophie Marbaix
    Clinical Drug Investigation, 2009, 29 : 655 - 665
  • [23] COST-UTILITY ANALYSIS OF VARENICLINE VS EXISTING SMOKING CESSATION STRATEGIES IN EL SALVADOR
    Lutz, M. A.
    Lovato, P.
    Morales, G.
    Cuesta, G.
    VALUE IN HEALTH, 2011, 14 (07) : A496 - A496
  • [24] A cost-effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease
    Lock, Kevin
    Wilson, Koo
    Murphy, Daniel
    Antonio Riesco, Juan
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (17) : 2613 - 2626
  • [25] Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers
    Linden, Kari
    Jormanainen, Vesa
    Linna, Miika
    Sintonen, Harri
    Wilson, Koo
    Kotomaki, Teija
    CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (03) : 549 - 560
  • [26] Using cost-effectiveness analysis to support policy change: varenicline and nicotine replacement therapy for smoking cessation in Jordan
    Madae'en, Saba
    Obeidat, Nour
    Adeinat, Mohammad
    JOURNAL OF PHARMACEUTICAL POLICY AND PRACTICE, 2020, 13 (01)
  • [27] Using cost-effectiveness analysis to support policy change: varenicline and nicotine replacement therapy for smoking cessation in Jordan
    Saba Madae’en
    Nour Obeidat
    Mohammad Adeinat
    Journal of Pharmaceutical Policy and Practice, 13
  • [28] Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation-results from four European countries
    Bolin, Kristian
    Wilson, Koo
    Benhaddi, Hicham
    de Nigris, Enrico
    Marbaix, Sophie
    Mork, Ann-Christin
    Aubin, Henri-Jean
    EUROPEAN JOURNAL OF PUBLIC HEALTH, 2009, 19 (06): : 650 - 654
  • [29] Cost-effectiveness of possible future smoking cessation strategies in Hungary: results from the EQUIPTMOD
    Nemeth, Bertalan
    Jozwiak-Hagymasy, Judit
    Kovacs, Gabor
    Kovacs, Attila
    Demjen, Tibor
    Huber, Manuel B.
    Cheung, Kei-Long
    Coyle, Kathryn
    Lester-George, Adam
    Pokhrel, Subhash
    Voko, Zoltan
    ADDICTION, 2018, 113 : 76 - 86
  • [30] COST-BENEFIT ANALYSIS OF VARENICLINE VS. EXISTING SMOKING CESSATION STRATEGIES IN PREGNANT WOMEN
    Barnard, M.
    Price, J.
    VALUE IN HEALTH, 2010, 13 (03) : A199 - A199
12345